文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

美国2015至2023年HIV暴露后预防处方趋势

Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015-2023.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该研究分析IQVIA真实世界纵向处方数据库,识别2015至2023年接受CDC推荐方案或标签外BIC/FTC/TAF进行HIV暴露后预防(PEP)的≥16岁人群。

要点

  • 2023年BIC/FTC/TAF方案使用者7536人,占16.8%。
  • 2023年88.4%的PEP使用者获得了28-30天完整疗程。

核心结论

  • PEP使用呈逐年增加趋势,可能反映PEP意识提高和HIV预防工作扩大。
  • 2023年基于比克替拉韦的PEP方案使用增加,提示处方实践转变,可能因其每日一次给药和高耐受性。

研究设计与样本

  • 分析IQVIA真实世界数据-纵向处方数据库,识别2015至2023年≥16岁接受CDC推荐PEP方案或标签外BIC/FTC/TAF者。
  • 排除已诊断HIV或接受抗逆转录病毒药物治疗HIV或乙型肝炎者,由两名临床医生复核处方确认可能为PEP。

主要发现

  • 基于比克替拉韦的PEP方案使用者从2018年1377人(占4.1%)增至2023年7536人(占16.8%)。
  • 2023年88.4%的PEP使用者获得28-30天完整疗程。

临床怎么用

  • PEP处方量逐年增加,临床应关注PEP可及性与规范使用。
  • 基于比克替拉韦的PEP方案使用增多,其每日一次给药和高耐受性可能影响处方选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIV postexposure prophylaxis (PEP) is the only intervention for reducing HIV acquisition risk after exposure. Our objective was to describe PEP user characteristics and analyze national trends in PEP regimens recommended by the Centers for Disease Control and Prevention (CDC) in 2016 and of off-label bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for PEP. METHODS: We analyzed the IQVIA Real World Data-Longitudinal Prescriptions database to identify persons aged ≥16 years prescribed antiretroviral (ARV) PEP regimens recommended by CDC or BIC/FTC/TAF from 2015 to 2023. We excluded persons with an HIV diagnosis or prescribed ARVs for HIV or hepatitis B virus treatment. Two clinicians reviewed regimens to confirm probable PEP prescriptions. We reported an annual number of PEP users, stratified by demographic characteristics, regimen type, and days of supply. RESULTS: The number of persons prescribed PEP increased from 20 618 in 2015 to 44 934 in 2023. The number of persons prescribed a bictegravir-based PEP regimen increased from 1377 (4.1% of total PEP users) in 2018 to 7536 (16.8%) in 2023. Among 44 934 PEP users in 2023, 53.8% were men, and 39.8% were aged 25-34 years. Most (88.4%) PEP users were prescribed a full course of PEP (28-30-day supply). CONCLUSIONS: Our analysis found an increasing trend in PEP use annually, possibly reflecting greater PEP awareness and broader HIV prevention efforts. Increased use of a bictegravir-based PEP regimen in 2023 suggests a shift in PEP prescribing practices, likely due to its once-daily dosing and high tolerability. Our findings can guide future recommendations for PEP medications.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Le JN, Zhu W, Huang YA, et al. Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015-2023. Clin Infect Dis. 2026. PMID: 41100695. doi:10.1093/cid/ciaf581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。